{
    "organizations": [],
    "uuid": "32dbfb3a9ba3032810faca231981970b4b0e0103",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-editas-medicine-q4-loss-per-share/brief-editas-medicine-q4-loss-per-share-0-84-idUSASB0C91G",
    "ord_in_thread": 0,
    "title": "BRIEF-Editas Medicine Q4 Loss Per Share $0.84",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - Editas Medicine Inc:\n* EDITAS MEDICINE ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND UPDATE\n* Q4 LOSS PER SHARE $0.84 * EDITAS MEDICINE - EDIT-101 FOR LEBER CONGENITAL AMAUROSIS TYPE 10 ON TRACK FOR MID-2018 INVESTIGATIONAL NEW DRUG FILING\n* YEAR-END CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $329 MILLION EXPECTED TO FUND BUSINESS FOR AT LEAST 24 MONTHS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-07T05:40:00.000+02:00",
    "crawled": "2018-03-07T19:45:13.028+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "editas",
        "medicine",
        "inc",
        "editas",
        "medicine",
        "announces",
        "fourth",
        "quarter",
        "full",
        "year",
        "result",
        "update",
        "q4",
        "loss",
        "per",
        "share",
        "editas",
        "medicine",
        "leber",
        "congenital",
        "amaurosis",
        "type",
        "track",
        "investigational",
        "new",
        "drug",
        "filing",
        "cash",
        "cash",
        "equivalent",
        "marketable",
        "security",
        "million",
        "expected",
        "fund",
        "business",
        "least",
        "month",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}